Media stories about Nivalis Therapeutics (NASDAQ:ALPN) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nivalis Therapeutics earned a coverage optimism score of 0.02 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.0893722474893 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of brokerages have recently issued reports on ALPN. Zacks Investment Research downgraded Nivalis Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 10th. ValuEngine cut Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Ladenburg Thalmann Financial Services started coverage on Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 price target for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $7.79.
Shares of Nivalis Therapeutics (NASDAQ ALPN) traded up 3.13% during trading on Tuesday, hitting $8.90. The stock had a trading volume of 19,882 shares. The stock’s 50-day moving average is $8.84 and its 200-day moving average is $9.73. The stock’s market cap is $11.93 million. Nivalis Therapeutics has a 12-month low of $7.20 and a 12-month high of $37.40.
In other Nivalis Therapeutics news, insider Value Fund L. P. Biotechnology purchased 17,806 shares of the stock in a transaction dated Tuesday, June 20th. The stock was bought at an average price of $2.25 per share, for a total transaction of $40,063.50. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Value Fund L. P. Biotechnology purchased 72,650 shares of the stock in a transaction dated Wednesday, June 7th. The shares were acquired at an average price of $2.29 per share, with a total value of $166,368.50. The disclosure for this purchase can be found here. Insiders acquired a total of 127,356 shares of company stock valued at $290,564 in the last 90 days. Corporate insiders own 9.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Nivalis Therapeutics (ALPN) Given Daily News Sentiment Rating of 0.02” was first posted by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-nivalis-therapeutics-alpn-share-price/1525109.html.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with our FREE daily email newsletter.